Brief: Medivir: Safety And Efficacy Data From MIV-711 Phase II Open Label Extension Study Presented At OARSI World Congress
06/05/2019 07:37
May 6 (Reuters) - Medivir AB MVIRb.ST :
* SAFETY AND EFFICACY DATA FROM THE MIV-711 PHASE II OPEN
LABEL
EXTENSION STUDY PRESENTED AT THE OARSI WORLD CONGRESS
* STUDY DEMONSTRATED THAT MIV-711 HAS ACCEPTABLE SAFETY AND
TOLERABILITY IN KNEE OSTEOARTHRITIS PATIENTS
Source text for Eikon: ID:nWkr7RPQ01
Further company coverage: MVIRb.ST
(Gdynia Newsroom)
((gdynia.newsroom@thomsonreuters.com; +48 58 772 0920;))